(e,e,e,e)-squalene is a lipid of Fatty Acyls (FA) class. (e,e,e,e)-squalene is associated with abnormalities such as Hypercholesterolemia and Cataract. The involved functions are known as Process, metaplastic cell transformation, Protein Overexpression, Anabolism and Biosynthetic Pathways. (e,e,e,e)-squalene often locates in Membrane, Protoplasm, Plasma membrane, Tissue membrane and Back. The associated genes with (e,e,e,e)-squalene are Genome, IMPACT gene, GAPDH gene, GTF2I gene and Chromatin. The related lipids are Membrane Lipids, cycloartenol, Sterols, Fatty Acids and Nonesterified Fatty Acids.
To understand associated biological information of (e,e,e,e)-squalene, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
(e,e,e,e)-squalene is suspected in Hypercholesterolemia, Cataract and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with (e,e,e,e)-squalene
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
There are no associated biomedical information in the current reference collection.
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Michael-Jubeli R et al. | High-temperature gas chromatography-mass spectrometry for skin surface lipids profiling. | 2011 | J. Lipid Res. | pmid:20952798 |
Lama-Muñoz A et al. | New hydrothermal treatment of alperujo enhances the content of bioactive minor components in crude pomace olive oil. | 2011 | J. Agric. Food Chem. | pmid:21265536 |
Ellebedy AH et al. | Inflammasome-independent role of the apoptosis-associated speck-like protein containing CARD (ASC) in the adjuvant effect of MF59. | 2011 | Proc. Natl. Acad. Sci. U.S.A. | pmid:21270336 |
Morel S et al. | Adjuvant System AS03 containing α-tocopherol modulates innate immune response and leads to improved adaptive immunity. | 2011 | Vaccine | pmid:21256188 |
Nowosielski M and Hoffmann M | Do the substituent effects affect conformational freedom of squalene in hopene biosynthesis? | 2011 | J Mol Model | pmid:21562825 |
Hernández-GarcÃa I et al. | [Adverse events after administration of A/H1N1 vaccine to patients]. | 2011 | Med Clin (Barc) | pmid:20199781 |
Fenoglio D et al. | MF-59 adjuvant influence on the functions of gammadelta T cells in HIV-1+ adults immunized with influenza seasonal vaccine. | 2011 | J Prev Med Hyg | pmid:22010544 |
Precioso AR et al. | A phase I randomized, double-blind, controlled trial of 2009 influenza A (H1N1) inactivated monovalent vaccines with different adjuvant systems. | 2011 | Vaccine | pmid:21945258 |
Fox CB et al. | Effects of emulsifier concentration, composition, and order of addition in squalene-phosphatidylcholine oil-in-water emulsions. | 2011 | Pharm Dev Technol | pmid:20550484 |
Tsai TF | MF59 adjuvanted seasonal and pandemic influenza vaccines. | 2011 | Yakugaku Zasshi | pmid:22129867 |
Puig-Barberà J et al. | MF59™-adjuvanted seasonal influenza vaccine in young children. | 2011 | Expert Rev Vaccines | pmid:22043952 |
Viganò A et al. | Long-term immunogenicity after one and two doses of a monovalent MF59-adjuvanted A/H1N1 Influenza virus vaccine coadministered with the seasonal 2009-2010 nonadjuvanted Influenza virus vaccine in HIV-infected children, adolescents, and young adults in a randomized controlled trial. | 2011 | Clin. Vaccine Immunol. | pmid:21795458 |
Huijskens E et al. | Immunogenicity, boostability, and sustainability of the immune response after vaccination against Influenza A virus (H1N1) 2009 in a healthy population. | 2011 | Clin. Vaccine Immunol. | pmid:21795459 |
Pollard AJ and Hill AV | Antibody repertoire: embracing diversity. | 2011 | Sci Transl Med | pmid:21795586 |
Okike IO et al. | The immunogenicity of a novel A (H1N1) vaccine in HIV-infected children. | 2011 | Vaccine | pmid:21742005 |
Kowert BA and Watson MB | Diffusion of organic solutes in squalane. | 2011 | J Phys Chem B | pmid:21780767 |
Mackay D and Jones PJ | Evaluation of methods for the determination of cholesterol absorption and synthesis in humans. | 2011 | Atherosclerosis | pmid:21763652 |
Jawaid AM et al. | Shape-controlled colloidal synthesis of rock-salt lead selenide nanocrystals. | 2011 | ACS Nano | pmid:21770427 |
Launay O et al. | Safety and immunogenicity of a monovalent 2009 influenza A/H1N1v vaccine adjuvanted with AS03A or unadjuvanted in HIV-infected adults: a randomized, controlled trial. | 2011 | J. Infect. Dis. | pmid:21628666 |
Piccialli V et al. | Isolation of a bis-iodurated tetra-THF as a trace product from the oxidation of squalene with RuOâ‚„ and its double ring expansion to a novel bis-THF-bis-THP compound. | 2011 | Molecules | pmid:21709619 |
Iannazzo S | Pharmacoeconomic evaluation of the MF59--adjuvanted influenza vaccine in the elderly population in Italy. | 2011 | J Prev Med Hyg | pmid:21710816 |
Seubert A et al. | Adjuvanticity of the oil-in-water emulsion MF59 is independent of Nlrp3 inflammasome but requires the adaptor protein MyD88. | 2011 | Proc. Natl. Acad. Sci. U.S.A. | pmid:21690334 |
Khurana S et al. | MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines. | 2011 | Sci Transl Med | pmid:21632986 |
Zhang LW et al. | Oil components modulate the skin delivery of 5-aminolevulinic acid and its ester prodrug from oil-in-water and water-in-oil nanoemulsions. | 2011 | Int J Nanomedicine | pmid:21556344 |
Lens M and Podesta Marty MH | Assessment of the kinetics of the antioxidative capacity of topical antioxidants. | 2011 | J Drugs Dermatol | pmid:21369642 |
Cristiani C et al. | Safety of MF-59 adjuvanted vaccine for pandemic influenza: results of the vaccination campaign in an Italian health district. | 2011 | Vaccine | pmid:21396903 |
Tsai TF et al. | Explorations of clinical trials and pharmacovigilance databases of MF59®-adjuvanted influenza vaccines for associated cases of narcolepsy. | 2011 | Scand. J. Infect. Dis. | pmid:21534891 |
Esposito S et al. | Influenza A/H1N1 MF59-adjuvanted vaccine in preterm and term children aged 6 to 23 months. | 2011 | Pediatrics | pmid:21464195 |
Esposito S et al. | An open-label, randomized clinical trial assessing immunogenicity, safety and tolerability of pandemic influenza A/H1N1 MF59-adjuvanted vaccine administered sequentially or simultaneously with seasonal virosomal-adjuvanted influenza vaccine to paediatric kidney transplant recipients. | 2011 | Nephrol. Dial. Transplant. | pmid:20974645 |
Durando P et al. | Adjuvants and alternative routes of administration towards the development of the ideal influenza vaccine. | 2011 Jan-Feb | Hum Vaccin | pmid:21245655 |
Schellenberger MT et al. | Evaluation of adjuvants for a candidate conjugate vaccine against benzo[a]pyrene. | 2011 Jan-Feb | Hum Vaccin | pmid:21245662 |
Dorea JG | Safety of thimerosal in vaccines: for whom and how many doses? | 2011 Mar-Apr | Therapie | pmid:23189333 |
Kozlov VG and Viktorova EG | [Evaluation of the efficiency and reactogenicity of emulsion-based adjuvant systems in the manufacture of polyclonal enteroviral diagnostic sera]. | 2011 Mar-Apr | Vopr. Virusol. | pmid:21545042 |
Ikematsu H et al. | Evaluation of immune response following one dose of an AS03A-adjuvanted H1N1 2009 pandemic influenza vaccine in Japanese adults 65 years of age or older. | 2012 | Hum Vaccin Immunother | pmid:22854661 |
Nakazawa A et al. | Optimization of culture conditions of the thraustochytrid Aurantiochytrium sp. strain 18W-13a for squalene production. | 2012 | Bioresour. Technol. | pmid:22023965 |
Niehaus TD et al. | Functional identification of triterpene methyltransferases from Botryococcus braunii race B. | 2012 | J. Biol. Chem. | pmid:22241476 |
Iorio AM et al. | Influenza viruses and cross-reactivity in healthy adults: humoral and cellular immunity induced by seasonal 2007/2008 influenza vaccination against vaccine antigens and 2009 A(H1N1) pandemic influenza virus. | 2012 | Vaccine | pmid:22245606 |
Ambrose CS and Belshe RB | Influenza vaccine in young children. | 2012 | N. Engl. J. Med. | pmid:22276839 |
Heikkinen T and Heinonen S | Influenza vaccine in young children. | 2012 | N. Engl. J. Med. | pmid:22276840 |
Fukase H et al. | Assessment of the immunogenicity and safety of varying doses of an MF59®-adjuvanted cell culture-derived A/H1N1 pandemic influenza vaccine in Japanese paediatric, adult and elderly subjects. | 2012 | Vaccine | pmid:22472791 |
Suthiwong J et al. | A new phenolic compound from the stem of Hymenocardia wallichii. | 2012 | J Asian Nat Prod Res | pmid:22423644 |
Zhang XH et al. | Chemical composition of volatile oils from the pericarps of Indian sandalwood (Santalum album) by different extraction methods. | 2012 | Nat Prod Commun | pmid:22428257 |
Guzmán Herrador BR et al. | Usefulness of health registries when estimating vaccine effectiveness during the influenza A(H1N1)pdm09 pandemic in Norway. | 2012 | BMC Infect. Dis. | pmid:22429643 |
Hatz C et al. | A randomized clinical trial to identify the optimal antigen and MF59(®) adjuvant dose of a monovalent A/H1N1 pandemic influenza vaccine in healthy adult and elderly subjects. | 2012 | Vaccine | pmid:22446638 |
Lai RP et al. | Mixed adjuvant formulations reveal a new combination that elicit antibody response comparable to Freund's adjuvants. | 2012 | PLoS ONE | pmid:22509385 |
Marinaro M et al. | A caprine herpesvirus 1 vaccine adjuvanted with MF59â„¢ protects against vaginal infection and interferes with the establishment of latency in goats. | 2012 | PLoS ONE | pmid:22511971 |
Desmaële D et al. | Squalenoylation: a generic platform for nanoparticular drug delivery. | 2012 | J Control Release | pmid:21840355 |
Czajka H et al. | A phase II, randomised clinical trial to demonstrate the non-inferiority of low-dose MF59-adjuvanted pre-pandemic A/H5N1 influenza vaccine in adult and elderly subjects. | 2012 | J Prev Med Hyg | pmid:23362618 |
Takami T et al. | A genetic and pharmacological analysis of isoprenoid pathway by LC-MS/MS in fission yeast. | 2012 | PLoS ONE | pmid:23145048 |
Langley JM et al. | A randomized, controlled non-inferiority trial comparing A(H1N1)pmd09 vaccine antigen, with and without AS03 adjuvant system, co-administered or sequentially administered with an inactivated trivalent seasonal influenza vaccine. | 2012 | BMC Infect. Dis. | pmid:23110320 |